LATITUDE
LATITUDE established abiraterone at first metastatic diagnosis for high-risk disease.
1,199 men; OS 53.3 vs 36.5 months (HR 0.66) at final analysis.
- Median 53.3 vs 36.5 months with ADT + abiraterone compared with ADT + placebo; about 16.8 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 34 percent lower chance of the event at any given time (hazard ratio 0.66, likely range 0.56 to 0.78).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: High-risk de novo metastatic hormone-sensitive prostate cancer: ADT + abiraterone vs ADT. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
1,199 participants enrolled.
| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Overall survivalprimary | ADT + abiraterone | 597 | 53.3 months | 0.66 (0.56–0.78) | <0.0001 | link |
| ADT + placebo | 602 | 36.5 months |
Pages like this
not linked directly; found by shared links- TrialPEACE-1
Shares Karim Fizazi, Abiraterone acetate, Prostate cancer.
- TrialALSYMPCA
Shares Karim Fizazi, Prostate cancer.
- TrialPROpel
Shares Abiraterone acetate, Prostate cancer.
- TrialMAGNITUDE
Shares Abiraterone acetate, Prostate cancer.
- PersonRobert A. Gatenby
Shares Abiraterone acetate, Prostate cancer.
- ProductBicalutamide
Shares Androgen receptor pathway inhibitor (ARPI), Prostate cancer.
- TermAndrogen deprivation therapy (ADT)
Shares Androgen receptor pathway inhibitor (ARPI), mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Prostate cancer.
- TrialSTAMPEDE
Shares mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer), Abiraterone acetate, Prostate cancer.